Announcement under Regulation 30
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sandu Pharmaceuticals' board met on May 28, 2025 and approved audited standalone and consolidated financial results for Q4 and the full year ended March 31, 2025. The board recommended a final dividend of Rs. 0.80 per equity share (8% on face value of Rs. 10), subject to shareholder approval. It appointed M/s Swapnil J Dixit and Associates as Secretarial Auditor for five years (FY26–FY30) and M/s Shekhar Joshi & Co as Cost Auditor for FY26. The company also approved reclassifying Akshath Finvest and Properties Private Limited (holding 4,94,182 shares or 5.12%) from the promoter group to public category shareholders. The filing notes that the company sold its entire stake in wholly owned subsidiary Sandu Phytoceuticals Private Limited on August 10, 2024, which has since been struck off from MCA records, making the FY25 results essentially standalone from Q3 FY25 onwards.
Shareholders will receive an 8% final dividend if approved at the AGM, and the exit from the non-material subsidiary simplifies the company's structure to a pure standalone entity. The promoter reclassification slightly reduces the promoter group's shareholding footprint, though no major financial red flags are evident from this filing.